

MedLife Group ends FY 2020 with an increase of 25.5% compared to prior year. "We will continue to be receptive and proactive to all that this pandemic brings, prioritizing the health of our patients and the support of society as a whole through medical research activities"

- Rapid adaptation to the new social and economic context, but also the calibration of the operational structure helped the company to keep up with the needs of the patients in a pandemic context.
- Despite revenue declines in March and April, MedLife managed to reach a pro-forma turnover of over a quarter of a billion euros last year
- In addition, the company has seen a gradual improvement in profitability, in line with the strategy of recent years
- Beyond financial performance, MedLife has managed to play a key role in society and gain detached leadership in pandemic monitoring through active involvement in the research area. These efforts will intensify
- MedLife will continue to strengthen its position nationwide through acquisition projects and, as opportunities arise, the company plans to test the market in the region as well.

Development plans for this year will also include the gradual development of MedPark project

February 26, 2021, Bucharest: MedLife Medical System, the leader of the private medical services market in Romania, announces the end of 2020 with a consolidated pro-forma turnover of RON 1.214 million (251 million euros), thus registering an increase of 25.5% compared to 2019.

Despite the pandemic context and the health crisis, MedLife continued to operate intensively. The rapid adaptation to the new social context and the proper calibration of the operational structure, helped the company to achieve a good performance in 2020 and to gradually improve its profitability in line with the strategy of recent years.

The development of COVID-19 laboratory network, in a timely manner, was one of the important achievements of the group last year. Through them, MedLife was able to periodically test the medical and support staff, to keep the employees and, implicitly, the patients safe and to keep the network of clinics and hospitals functional, ensuring a quality medical act. Moreover, MedLife group focused on helping patients and state institutions by conducting COVID-19 tests and relieving public hospitals by taking in chronic patients. At the same time, the company has run numerous support programs for various disadvantaged groups in a pandemic context.

A very important segment of investment and development in 2020 was the group's research division. The company has conducted numerous research studies on the evolution of the new virus in Romania, managing to play an important role at the societal level in monitoring the

pandemic. For this year, MedLife representatives want to intensify the work of the group's research division and, in this regard, expressed their intention to expand the SARS CoV 2 virus sequencing program, but also to launch new studies to further support authorities in fighting against the pandemic.

"It was a difficult year, full of challenges and tense for most of us. From the first signals at local level, we realized that it will not be something transient, so we mobilized, worked on several scenarios and adapted to the new conditions. We have launched new screening programs for patients with chronic diseases, but also for those who had SARS CoV2 infection, we have invested in research conducting national premier studies on natural immunization for COVID 19, virus sequencing or antibody dynamics after infection and post vaccine and, last but not least, we have constantly run testing programs to keep colleagues, doctors and nurses in all our units safe. All these measures helped us not only to adapt to the new economic reality, but also to optimize the business dynamics for the next period. We are ready to capture the revenues that will come from the post-pandemic recovery period", said Mihai Marcu, President and CEO of MedLife Group.

MedLife Group also registered a dynamic activity in the area of corporate clients. Thus, since the beginning of the COVID-19 pandemic, the company has developed new products to meet the needs in this epidemiological context: from online consultations and digitization of occupational medicine services, to programs on safe restarting of businesses , consultancy regarding epidemiological triage or COVID testing campaigns at the company's headquarters. Moreover, starting from the pandemic context and having a solid basis of historical results, MedLife has launched a new program focusing on anticipating certain trends in health in an industry / company and customizing medical services so as to reduce the risks of various pathologies among employees. In essence, the new program will help companies to protect their employees and customers and thus reduce costs and increase productivity.

"It is a unique approach in Romania based on the principles of personalized medicine. Thus, based on an extensive analysis of medical history and information on the particularities of each industry and company, we will be able to offer customized medical programs to help reduce the risk of various pathologies among employees. Basically, we can act very targeted on each team, and based on the assessment of risk factors, diseases, adverse effects on business, we can adapt medical programs so as to improve the health of employees and help companies to propel. In this way, the partner companies will be able not only to take care of the employees' health, but also to decrease expenses and increase productivity levels" declared Mihai Marcu.

For 2021, the company's representatives announce that they will continue to be receptive and proactive to everything that this pandemic brings, but, at the same time, they will continue the post-COVID development and expansion plans.

"We are connected to everything that means the current economic dynamics, we have development and expansion plans and we are ready to move forward, but we are looking carefully at the market, to take action when needed. We will continue to have as a priority the health and safety of our patients, we will constantly adapt to their current needs, burdened by the pandemic context. From an operational point of view, we want to consolidate our position on the Romanian

market, which we consider very important and with great potential for development, and, insofar as there will be opportunities, we want to test the market in the region as well.

We have credit lines that are dedicated both to M&A program and the development of projects aimed at recovering the post-COVID patient, having at our disposal the new increase, amounting to 20 million euros, to which are added important cash generated by our business divisions. At the same time, we will continue, gradually, the development of MedLife Medical Park project, which has the potential to become in the next period the most complex medical project in Romania and will be easily compared with other large medical entities in Europe. The new investments and acquisitions will be carefully calibrated according to the evolution of the pandemic ", specified Mihai Marcu, President and CEO of MedLife Group.